Skip to main content
. Author manuscript; available in PMC: 2020 Feb 28.
Published in final edited form as: Cancer Lett. 2018 Aug 2;439:91–100. doi: 10.1016/j.canlet.2018.07.034

Fig. 6. In vitro and in vivo activity of duloxetine (Dul) on K-Luc gliomas.

Fig. 6.

(A) Dul inhibited K-Luc proliferation even at low concentrations. n = 3 ± SD. *: p < 0.05. (B) Dul did not inhibit brain S100B or RAGE protein levels in tumor-bearing animals. One day after K-Luc implantation, tumor-bearing mice were treated daily with Dul or vehicle. Fourteen days later, tumors and peritumoral tissue was harvested for protein analysis. (n = 3 mice/group ± SD). (C) Representative immunohistochemistry of i.c. K-Luc tumors (T) following a two-week treatment with Dul demonstrating persistent S100B expression by peritumoral astrocytes (GFAP+ cells). (D) Dul did not inhibit K-Luc tumor growth. Tumor bearing mice were treated with daily vehicle or Dul for 14 days (n =6 mice/group). Animals demonstrating signs of elevated intracranial pressure were euthanized and tumor presence confirmed by histology. MS: median survival. Results are representative of two separate experiments.